An article in the New York Times Sunday Review section of November 29, 2014, discusses the use of psilocybin for treating depression and other serious medical conditions. Writer Eugenia Bone, the author of Mycophilia: Revelations From the Weird World of Mushrooms, covers the history and culture of “magic mushrooms” from the fringes of mycology to the latest scientific research.
“Psilocybin could have enormous impact on the lives of many Americans. But at the moment, its Schedule 1 status makes it a difficult drug to study, and only a handful of scientists are engaged in its research. This needs to change. Rescheduling psilocybin won’t make it legal; it will make it easier for research to be conducted, leading to more scientists exploring its potential, while reducing investor concern and allowing for compassionate use provisions.”